Literature DB >> 22171322

Stable isotope labeling with amino acids in cell culture (SILAC)-based quantitative proteomics study of a thyroid hormone-regulated secretome in human hepatoma cells.

Cheng-Yi Chen1, Lang-Ming Chi, Hsiang-Cheng Chi, Ming-Ming Tsai, Chung-Ying Tsai, Yi-Hsin Tseng, Yang-Hsiang Lin, Wei-Jan Chen, Ya-Hui Huang, Kwang-Huei Lin.   

Abstract

The thyroid hormone, 3, 3',5-triiodo-l-thyronine (T(3)), regulates cell growth, development, differentiation, and metabolism via interactions with thyroid hormone receptors (TRs). However, the secreted proteins that are regulated by T(3) are yet to be characterized. In this study, we used the quantitative proteomic approach of stable isotope labeling with amino acids in cell culture coupled with nano-liquid chromatography-tandem MS performed on a LTQ-Orbitrap instrument to identify and characterize the T(3)-regulated proteins secreted in human hepatocellular carcinoma cell lines overexpressing TRα1 (HepG2-TRα1). In total, 1742 and 1714 proteins were identified and quantified, respectively, in three independent experiments. Among these, 61 up-regulated twofold and 11 down-regulated twofold proteins were identified. Eight proteins displaying increased expression and one with decreased expression in conditioned media were validated using Western blotting. Real-time quantitative RT-PCR further disclosed induction of plasminogen activator inhibitor-1 (PAI-1), a T(3) target, in a time-course and dose-dependent manner. Serial deletions of the PAI-1 promoter region and subsequent chromatin immunoprecipitation assays revealed that the thyroid hormone response element on the promoter is localized at positions -327/-312. PAI-1 overexpression enhanced tumor growth and migration in a manner similar to what was seen when T(3) induced PAI-1 expression in J7-TRα1 cells, both in vitro and in vivo. An in vitro neutralizing assay further supported a crucial role of secreted PAI-1 in T(3)/TR-regulated cell migration. To our knowledge, these results demonstrate for the first time that proteins involved in the urokinase plasminogen activator system, including PAI-1, uPAR, and BSSP4, are augmented in the extra- and intracellular space of T(3)-treated HepG2-TRα1 cells. The T(3)-regulated secretome generated in the current study may provide an opportunity to establish the mechanisms underlying T(3)-associated tumor progression and prognosis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22171322      PMCID: PMC3322565          DOI: 10.1074/mcp.M111.011270

Source DB:  PubMed          Journal:  Mol Cell Proteomics        ISSN: 1535-9476            Impact factor:   5.911


  77 in total

1.  Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin.

Authors:  D A Waltz; L R Natkin; R M Fujita; Y Wei; H A Chapman
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

2.  Direct regulation of androgen receptor-associated protein 70 by thyroid hormone and its receptors.

Authors:  Pei-Ju Tai; Ya-Hui Huang; Chung-Hsuan Shih; Ruey-Nan Chen; Chi-De Chen; Wei-Jan Chen; Chia-Siu Wang; Kwang-Huei Lin
Journal:  Endocrinology       Date:  2007-04-05       Impact factor: 4.736

3.  Thyroid hormone analogs and metabolites: new applications for an old hormone?

Authors:  P Reed Larsen
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2009-01

4.  Thyroid hormone receptor beta2 promoter activity in pituitary cells is regulated by Pit-1.

Authors:  W M Wood; J M Dowding; T M Bright; M T McDermott; B R Haugen; D F Gordon; E C Ridgway
Journal:  J Biol Chem       Date:  1996-09-27       Impact factor: 5.157

5.  A new in vitro assay for quantitating tumor cell invasion.

Authors:  L A Repesh
Journal:  Invasion Metastasis       Date:  1989

Review 6.  Cysteine cathepsins: multifunctional enzymes in cancer.

Authors:  Mona Mostafa Mohamed; Bonnie F Sloane
Journal:  Nat Rev Cancer       Date:  2006-10       Impact factor: 60.716

7.  Urokinase-type plasminogen activator is a preferred substrate of the human epithelium serine protease tryptase epsilon/PRSS22.

Authors:  Shinsuke Yasuda; Nasa Morokawa; G William Wong; Andrea Rossi; Mallur S Madhusudhan; Andrej Sali; Yuko S Askew; Roberto Adachi; Gary A Silverman; Steven A Krilis; Richard L Stevens
Journal:  Blood       Date:  2005-02-08       Impact factor: 22.113

8.  Thyroid hormone binding to isolated human apolipoproteins A-II, C-I, C-II, and C-III: homology in thyroxine binding sites.

Authors:  S Benvenga; H J Cahnmann; D Rader; M Kindt; A Facchiano; J Robbins
Journal:  Thyroid       Date:  1994       Impact factor: 6.568

9.  Apolipoprotein E and paraoxonase 1 polymorphisms are associated with lower serum thyroid hormones in postmenopausal women.

Authors:  Irene Lambrinoudaki; George Kaparos; Demetrios Rizos; Fotini Galapi; Andreas Alexandrou; Theodoros N Sergentanis; Maria Creatsa; George Christodoulakos; E Kouskouni; D Botsis
Journal:  Clin Endocrinol (Oxf)       Date:  2008-11-09       Impact factor: 3.478

10.  Thyroid hormone receptor mutants implicated in human hepatocellular carcinoma display an altered target gene repertoire.

Authors:  I H Chan; M L Privalsky
Journal:  Oncogene       Date:  2009-09-14       Impact factor: 9.867

View more
  12 in total

Review 1.  Quantitative analysis of global phosphorylation changes with high-resolution tandem mass spectrometry and stable isotopic labeling.

Authors:  Hye Kyong Kweon; Philip C Andrews
Journal:  Methods       Date:  2013-04-21       Impact factor: 3.608

Review 2.  Thyroid hormone actions in liver cancer.

Authors:  Sheng-Ming Wu; Wan-Li Cheng; Crystal D Lin; Kwang-Huei Lin
Journal:  Cell Mol Life Sci       Date:  2012-09-06       Impact factor: 9.261

3.  The 4G/5G Polymorphism of Plasminogen Activator Inhibitor Type 1 is a Predictor of Moderate-to-Severe Thyroid Eye Disease.

Authors:  Monika Katko; Erika Galgoczi; Annamaria Erdei; Annamaria Gazdag; Eszter Berta; Miklos Bodor; Ildiko Seres; Ildiko Hircsu; Arpad Badics; Bernadett Ujhelyi; Livia Sira; Harjit Pal Bhattoa; Endre V Nagy
Journal:  J Inflamm Res       Date:  2021-05-12

4.  Thyroid hormone-mediated regulation of lipocalin 2 through the Met/FAK pathway in liver cancer.

Authors:  I-Hsiao Chung; Cheng-Yi Chen; Yang-Hsiang Lin; Hsiang-Cheng Chi; Ya-Hui Huang; Pei-Ju Tai; Chia-Jung Liao; Chung-Ying Tsai; Syuan-Ling Lin; Meng-Han Wu; Ching-Ying Chen; Kwang-Huei Lin
Journal:  Oncotarget       Date:  2015-06-20

5.  Thyroid hormone enhanced human hepatoma cell motility involves brain-specific serine protease 4 activation via ERK signaling.

Authors:  Cheng-Yi Chen; I-Hsiao Chung; Ming-Ming Tsai; Yi-Hsin Tseng; Hsiang-Cheng Chi; Chung-Ying Tsai; Yang-Hsiang Lin; You-Ching Wang; Chie-Pein Chen; Tzu-I Wu; Chau-Ting Yeh; Dar-In Tai; Kwang-Huei Lin
Journal:  Mol Cancer       Date:  2014-07-01       Impact factor: 27.401

Review 6.  Biological functions of thyroid hormone in placenta.

Authors:  Cheng-Yi Chen; Chie-Pein Chen; Kwang-Huei Lin
Journal:  Int J Mol Sci       Date:  2015-02-16       Impact factor: 5.923

Review 7.  Mass spectrometry-based proteomics in molecular diagnostics: discovery of cancer biomarkers using tissue culture.

Authors:  Debasish Paul; Avinash Kumar; Akshada Gajbhiye; Manas K Santra; Rapole Srikanth
Journal:  Biomed Res Int       Date:  2013-03-17       Impact factor: 3.411

Review 8.  Molecular functions of thyroid hormones and their clinical significance in liver-related diseases.

Authors:  Hsiang Cheng Chi; Cheng-Yi Chen; Ming-Ming Tsai; Chung-Ying Tsai; Kwang-Huei Lin
Journal:  Biomed Res Int       Date:  2013-06-26       Impact factor: 3.411

9.  Thyroid hormone upregulates zinc-α2-glycoprotein production in the liver but not in adipose tissue.

Authors:  Rafael Simó; Cristina Hernández; Cristina Sáez-López; Berta Soldevila; Manel Puig-Domingo; David M Selva
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

10.  Quercetin reduces cyclin D1 activity and induces G1 phase arrest in HepG2 cells.

Authors:  Jin Zhou; L U Li; L I Fang; Hua Xie; Wenxiu Yao; Xiang Zhou; Zhujuan Xiong; L I Wang; Zhixi Li; Feng Luo
Journal:  Oncol Lett       Date:  2016-05-27       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.